BBH - ETF AI Analysis
Top Page
VanEck Biotech ETF (BBH)
BBH, the VanEck Biotech ETF, reflects a generally solid quality profile, largely driven by heavyweight holdings like Amgen, Gilead Sciences, Vertex, and Regeneron, which all show strong financial performance, positive earnings sentiment, and supportive growth pipelines. These strengths are partly offset by weaker names such as Moderna and Revolution Medicines, where declining revenues, ongoing losses, and bearish technical trends introduce more volatility and risk. The main risk factor is the ETF’s concentrated exposure to the biotech sector, where high valuations, competitive pressures, and company-specific clinical and profitability challenges can lead to sharp swings in performance.
BBH vs. SPDR S&P 500 ETF (SPY)
- AUM
- 503.63M
- Region
- Global
- Expense Ratio
- 0.35%
- Beta
- 0.59
- Issuer
- VanEck
- Inception Date
- Dec 20, 2011
- Dividend Yield
- 0.38%
- Asset Class
- Equity
- Index Tracked
- MVIS US Listed Biotech 25
BBH Summary
The VanEck Biotech ETF (BBH) is a fund that follows the MVIS US Listed Biotech 25 Index and focuses on U.S. biotechnology companies. It holds firms that develop new medicines, genetic treatments, and medical tests, including well-known names like Amgen and Gilead Sciences. Someone might invest in BBH if they want growth potential from medical breakthroughs and a simple way to spread their money across many biotech stocks instead of picking just one. However, this ETF is heavily concentrated in biotech, so its price can swing a lot and may fall sharply if drug trials fail or health care stocks drop.
How much will it cost me?
The VanEck Biotech ETF (BBH) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused ETF that targets biotechnology companies, which often require more active management to track this specialized market. It’s important to consider whether the potential growth in this niche sector aligns with your investment goals.
What would affect this ETF?
The VanEck Biotech ETF (BBH) could benefit from advancements in biotechnology, such as breakthroughs in drug development and genetic research, as well as increased global demand for innovative health solutions. However, it may face challenges from regulatory hurdles, high research costs, and potential economic downturns that could impact funding for biotech companies. Additionally, changes in interest rates could affect the financial performance of its top holdings like Gilead Sciences and Amgen.
BBH Top 10 Holdings
BBH is a pure biotech play, with performance largely steered by a handful of heavyweight names. Amgen and Vertex have been steady to rising over the past few months, helping support the fund, while Regeneron has been more mixed and occasionally losing steam. The real spark lately comes from Moderna and Natera, both showing strong momentum that gives the ETF a growth-driven feel. With holdings spanning U.S. and global biotech innovators, BBH is concentrated in cutting-edge health care rather than broad market exposure.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 AMGN | Amgen | 16.16% | $81.39M | $236.98B | 45.56% | 77Outperform |
 GILD | Gilead Sciences | 13.61% | $68.54M | $194.07B | 23.77% | 78Outperform |
 VRTX | Vertex Pharmaceuticals | 7.95% | $40.06M | $132.95B | 23.05% | 78Outperform |
 MRNA | Moderna | 7.49% | $37.75M | $96.65B | 794.18% | 59Neutral |
 REGN | Regeneron | 6.80% | $34.28M | $83.13B | 39.07% | 78Outperform |
 NTRA | Natera | 4.75% | $23.94M | $58.51B | 121.20% | 73Outperform |
 IQV | IQVIA Holdings | 4.37% | $22.04M | $44.09B | 26.51% | 73Outperform |
 ARGX | Argenx Se | 4.09% | $20.61M | $55.56B | 6.62% | 79Outperform |
 ILMN | Illumina | 3.89% | $19.61M | $40.46B | 185.83% | 71Outperform |
 RVMD | Revolution Medicines | 3.97% | $20.01M | $41.64B | 263.21% | 52Neutral |
BBH Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBH, the sentiment is Positive. The current price of 250.46 is above the 20-day moving average (MA) of 241.73, above the 50-day MA of 237.53, and above the 200-day MA of 204.68, indicating a bullish trend. The MACD of 2.80 indicates Negative momentum. The RSI at 62.10 is Neutral, neither overbought nor oversold. The STOCH value of 85.34 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBH.
BBH Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| BBH | $250.46 | $267.00(6.60% Upside) | $503.63M | 0.35% | 71Outperform |
 BLOK | $56.43 | $93.90(66.40% Upside) | $944.79M | 0.70% | 58Neutral |
 GII | $73.22 | $81.90(11.86% Upside) | $938.53M | 0.40% | 63Neutral |
 AGIX | $45.09 | $63.88(41.67% Upside) | $749.02M | 1.00% | 60Neutral |
 CANC | $41.53 | $61.71(48.59% Upside) | $212.14M | 0.75% | 60Neutral |
 HTEC | $44.46 | $52.57(18.25% Upside) | $110.10M | 0.68% | 66Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BBH | VanEck Biotech ETF | 250.46 | 73.83 | 41.80% | |
| BLOK | Amplify Transformational Data Sharing Etf | 56.43 | -14.50 | -20.45% | |
| GII | SPDR S&P Global Infrastructure ETF | 73.22 | 4.73 | 6.91% | |
| AGIX | KraneShares Artificial Intelligence & Technology ETF | 45.09 | 7.13 | 18.78% | |
| CANC | Tema Oncology ETF | 41.53 | 11.51 | 38.32% | |
| HTEC | ROBO Global Healthcare Technology and Innovation ETF | 44.46 | 11.36 | 34.31% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.